You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
This randomised, double-blind, placebo-controlled single ascending dose study (n=29) tested prolonged intravenous DMT administration (30-s bolus (1.5-7.5mg) + 6-h infusion (4.4-33.3nl/ml)) in healthy volunteers. It found the treatment to be safe, with only mild, self-limiting adverse events, and observed mild psychedelic effects, reduced attention and stability, and decreased occipital alpha EEG power at higher doses, supporting further investigation in stroke recovery contexts.
Psychedelics A to Z offers an expansive and visually engaging exploration of its multifaceted subject.
The DOSED Education Center offers a 40-hour self-paced online course on psychedelics and mental health, featuring expert-led modules.
Learn to guide others through microdosing with this 12-week online training focused on practice, ethics, and client support skills.
This randomised, double-blind, placebo-controlled Phase III trial (n=140) will evaluate the efficacy and safety of a single oral dose of MM120 (100 µg LSD D-tartrate) for the treatment of major depressive disorder (MDD).
This randomised, double-blind, placebo-controlled Phase III trial (n=60) will investigate the efficacy and safety of subcutaneous ketamine (35-70mg/70kg, twice weekly for four weeks) as an add-on treatment for adolescents experiencing a major depressive episode with suicidal ideation and/or behaviour.
This randomised, quadruple-blind, placebo-controlled Phase II trial (n=50) will assess the effects of ketamine (52.5mg/70kg, intramuscularly, four times over two weeks) on opioid craving and withdrawal symptoms in adults newly entering methadone treatment for opioid use disorder.
This randomised, quadruple-blind, placebo-controlled Phase III trial (n=90) will study the effectiveness, safety, and tolerability of psilocybin (25 mg)–assisted therapy compared to an active placebo (1 mg psilocybin) in individuals with treatment-resistant depression associated with bipolar II disorder.
This open-label Phase II trial (n=20) will evaluate the feasibility, safety, and effectiveness of high-intensity inpatient MDMA-assisted psychotherapy for treatment-refractory posttraumatic stress disorder (PTSD). Participants will receive two MDMA sessions—first 80 mg plus 40 mg, then 120 mg plus 60 mg—integrated into a four-week inpatient therapy programme that includes manualised psychotherapy and non-drug preparatory and integrative sessions.
This secondary analysis (n=82) of a Phase III RCT of MDMA-assisted therapy found significant improvements in both uncompassionate self-responding and compassionate self-responding across all six Self-Compassion Scale subscales, most with large effect sizes. Changes in self-compassion fully mediated the reductions in PTSD severity and depressive symptoms observed with MDMA-AT versus placebo plus therapy, though no significant effects were seen for alcohol or substance use outcomes.
Psychedelic Database
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.
